Ascentage Pharma Group International 6855.HK 价格预测与展望

Q: 技术分析指标如何适用于 6855.HK？

根据技术分析，Ascentage Pharma Group International 的综合信号为 Strong Sell。Ascentage Pharma Group International 有 1 个买入信号，1 个中性信号和 5 个卖出信号。

Q: 6855.HK 的斐波那契回调水平是多少？

Ascentage Pharma Group International 的斐波那契回调水平是 在 23.6% 和 38.2% 之间。

Q: Ascentage Pharma Group International 的 RSI 是多少？

Ascentage Pharma Group International 的 RSI 目前为 33.58，表明处于 中立 状态

Q: Ascentage Pharma Group International 接下来 12 个月的价格是多少？

Ascentage Pharma Group International 6855.HK 接下来 12 个月的价格预计为 $101.66。

Q: Ascentage Pharma Group International 预计会涨到多高？

据华尔街分析师称，Ascentage Pharma Group International 预计将达到 $119.7 的高预测值。

主页

股票

6855.HK

预测

ASCENTAGE-B (6855.HK)

Ascentage Pharma Group International

HK$49

-0.88%

$-0.43

休市： Jan 29, 16:00:00 HKT

关键数据

前收盘价

$49.3

开盘价

$49.44

当日区间

$48.02 - $49.76

52周范围

$31.35 - $95.35

交易量

907.1K

平均成交量

1.9M

每股收益（TTM）

-4.01

股息收益率

市值

$18.2B

什么是 ASCENTAGE-B？

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.

功能特性

交易策略

资源

市场

Utilizing our sophisticated predictive model, we anticipate notable price fluctuations for 6855.HK in the upcoming periods. Looking toward the future, our 2027 projection indicates an average price target of $101.66. The lowest target is $89.89 and the highest is $119.7. Empower your investment choices with our cutting-edge, data-driven analysis!

6855.HK 股价预测摘要

6855.HK的顶级分析师评级

基于 13 位分析师对 6855.HK 的股票评级，更新于 Jan 01, 2026

Strong Buy

Strong buy

Buy

Hold

Sell

Strong sell

Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for 6855.HK. Our analysts highlight strong fundamentals and favorable market sentiment, positioning 6855.HK for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: 6855.HK is a Strong Buy candidate.

6855.HK stock price ended at $49.3 on 星期三, after dropping 0.28%

On the latest trading day Jan 28, 2026, the stock price of 6855.HK fell by 0.28%, dropping from $49.70 to $49.30. During the session, the stock saw a volatility of 2.53%, with prices oscillating between a daily low of $48.96 and a high of $50.20. On the latest trading day, the trading volume for 6855.HK rose by 71.7K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.4M shares were traded, with a market value of approximately $18.3B.

6855.HK 技术面信号

技术面信号摘要

购买信号 1

中性信号 1

卖出信号 5

Strong Sell

Sell

Neutral

Buy

Strong Buy

6855.HK目前显示1个买入信号和5个卖出信号。该股票自12:00 AM以来一直处于下降趋势状态，在此期间价格总变动为-0.28%。总体而言，技术指标显示中期前景为Strong Sell。

6855.HK 的看涨/看跌信号

我们的算法通过分析移动平均线、RSI、MACD 和成交量等关键指标，为 6855.HK 生成看涨和看跌信号。这些见解可助您做出明智的投资决策。

后续问题

技术分析指标如何适用于 6855.HK？



6855.HK 的斐波那契回调水平是多少？



Ascentage Pharma Group International 的 RSI 是多少？



Ascentage Pharma Group International 接下来 12 个月的价格是多少？



Ascentage Pharma Group International 预计会涨到多高？



Ascentage Pharma Group International（6855.HK）价格

6855.HK 股价走势图